Ocular Therapeutix Inc (OCUL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 41.74 is considered Undervalued compared with the five-year average of -8.69. The fair price of Ocular Therapeutix Inc (OCUL) is between 13.33 to 17.77 according to relative valuation method. Compared to the current price of 10.83 USD , Ocular Therapeutix Inc By Undervalued By 18.75%.

Relative Value

Fair Zone

13.33-17.77

Current Price：10.83

18.75%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Ocular Therapeutix Inc (OCUL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Ocular Therapeutix Inc (OCUL) has a current Price-to-Book (P/B) ratio of 8.01. Compared to its 3-year average P/B ratio of 20.49, the current P/B ratio is approximately -60.91% higher. Relative to its 5-year average P/B ratio of 15.29, the current P/B ratio is about -47.61% higher. Ocular Therapeutix Inc (OCUL) has a Forward Free Cash Flow (FCF) yield of approximately -7.92%. Compared to its 3-year average FCF yield of -13.24%, the current FCF yield is approximately -40.16% lower. Relative to its 5-year average FCF yield of -13.68%, the current FCF yield is about -42.10% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for OCUL competitors is 211.43, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL.O) exhibits a P/S ratio of 41.74, which is -80.26% above the industry average. Given its robust revenue growth of -22.43%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of OCUL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of OCUL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is OCUL currently overvalued or undervalued?

What is Ocular Therapeutix Inc (OCUL) fair value?

OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ocular Therapeutix Inc (OCUL) is between 13.33 to 17.77 according to relative valuation method.

How does OCUL's valuation metrics compare to the industry average?

The average P/S ratio for OCUL's competitors is 211.43, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL) exhibits a P/S ratio of 41.74, which is -80.26% above the industry average. Given its robust revenue growth of -22.43%, this premium appears unsustainable.

What is the current P/B ratio for Ocular Therapeutix Inc (OCUL) as of Mar 02 2026?

As of Mar 02 2026, Ocular Therapeutix Inc (OCUL) has a P/B ratio of 8.01. This indicates that the market values OCUL at 8.01 times its book value.

What is the current FCF Yield for Ocular Therapeutix Inc (OCUL) as of Mar 02 2026?

As of Mar 02 2026, Ocular Therapeutix Inc (OCUL) has a FCF Yield of -7.92%. This means that for every dollar of Ocular Therapeutix Inc's market capitalization, the company generates -7.92 cents in free cash flow.

What is the current Forward P/E ratio for Ocular Therapeutix Inc (OCUL) as of Mar 02 2026?

As of Mar 02 2026, Ocular Therapeutix Inc (OCUL) has a Forward P/E ratio of -8.49. This means the market is willing to pay $-8.49 for every dollar of Ocular Therapeutix Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ocular Therapeutix Inc (OCUL) as of Mar 02 2026?

As of Mar 02 2026, Ocular Therapeutix Inc (OCUL) has a Forward P/S ratio of 41.74. This means the market is valuing OCUL at $41.74 for every dollar of expected revenue over the next 12 months.

OCUL Valuation